NPM1-mutated/FLT3-wild type patients older than 65 years showed no statistically significant improved OS compared to all other molecularly define subsets, whereas the younger patients with NPM1-mutated/FLT3-wild type AML did show improved OS as predicted from earlier studies on younger patients with AML. Here, FLT3 is linked to acute myeloid leukemia.